Target intelligence / Profile preview

Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase (NS5B)

Target
NS5B
Molecular classification
Enzyme, RNA-directed RNA polymerase, Transferase
01

Overview

The Hepatitis C virus non-structural protein 5B (NS5B) is an RNA-dependent RNA polymerase (RdRp) essential for the replication of the HCV genome (UniProt: P26664). It functions as the catalytic core of the viral replication complex, utilizing a positive-sense RNA template to synthesize a negative-sense intermediate, which then serves as a template for new genomic RNA (PubMed: 11581170). Structurally, NS5B features a classic polymerase "right-hand" architecture consisting of fingers, palm, and thumb domains that coordinate the binding of RNA and ribonucleotide triphosphates (rNTPs) (PubMed: 10490630). As an enzyme with no human homolog, NS5B is a primary target for direct-acting antiviral (DAA) therapy, specifically through nucleoside analogs like sofosbuvir that cause chain termination and non-nucleoside inhibitors that bind allosteric sites (PubChem: CID 45375808). These therapies have revolutionized the treatment of chronic hepatitis C, offering high cure rates and reducing the risk of long-term complications such as cirrhosis and hepatocellular carcinoma (StatPearls: NBK448088).

Other names
HCV NS5BRNA-directed RNA polymeraseRdRpNS5B polymeraseNon-structural protein 5B
02

Mechanism of action

Nucleoside/nucleotide analogs (NIs) act as alternative substrates for the polymerase, leading to premature RNA chain termination; non-nucleoside inhibitors (NNIs) bind to allosteric sites on the enzyme (thumb or palm domains) to prevent the conformational changes required for the initiation or elongation of RNA synthesis (PubMed: 19131601).

03

Biological functions

Viral RNA replicationRNA-dependent RNA synthesisViral genome replication
04

Disease associations

InfectionHepatitis CLiver cirrhosisHepatocellular carcinoma
05

Safety considerations

Drug-drug interactions with P-glycoprotein (P-gp) inducersSymptomatic bradycardia when co-administered with amiodaroneEmergence of resistance-associated substitutions (RASs)Potential for hepatotoxicity in patients with decompensated cirrhosis
06

Interacting drugs

Sofosbuvir

5 more in the full profile.

07

Biomarkers

HCV RNA viral loadSustained Virologic Response (SVR12)NS5B resistance-associated substitutions (RASs) such as S282T

Beyond the preview

Go deeper on Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase (NS5B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase (NS5B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call